Drug intelligence / Profile preview

NuThrax

Development stage: Approved
Lead developer: Emergent BioSolutions
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NuThrax is an investigational vaccine designed for the prevention of anthrax disease caused by *Bacillus anthracis*. It is a next-generation anthrax vaccine candidate combining BioThrax (Anthrax Vaccine Adsorbed, AVA) with the immunostimulatory oligodeoxynucleotide adjuvant CPG 7909, a Toll-like receptor 9 (TLR9) agonist. The intent is to provide faster onset of protective immunity and require fewer doses than existing vaccines. NuThrax is being studied as an anthrax vaccine for use in the event of exposure and as a component of medical countermeasure stockpiles.

Brand names: NuThrax
Other names: AV7909AV-7909AV 7909Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant

Targets

TLR9 (Toll-like receptor 9)PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on NuThrax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuThrax.

Explore the full profile